Two days in February, two multi-billion-dollar deals in the Medical Device sector. But these aren’t your everyday deals for prosthesis, abdominal stents or novel surgical tools. Both target companies fall into the medical aesthetics category of medical devices, which includes body contouring and other cosmetic procedures that are generally cash-pay businesses.

On February 13, 2017, Allergan plc (NYSE: AGN) purchased ZELTIQ® Aesthetics, Inc. for $2.48 billion, or $56.50 per share. ZELTIQ® Aesthetics develops and commercializes products utilizing its controlled-cooling technology platform. Its flagship CoolSculpting system is FDA-cleared to affect appearance through lipolysis or reduction of unwanted fat using a patented cooling technology.

The acquisition of ZELTIQ is immediately accretive and will enhance Allergan’s global medical aesthetics portfolio. Body contouring, a $4 billion global market, will become the third pillar of Allergan’s global aesthetics portfolio.

The deal complements Allergan’s $2.9 billion purchase of Acelity’s LifeCell business unit in December 2016, which added LifeCell’s regenerative medicine and reconstructive surgery portfolio to Allergan’s portfolio of aesthetics and breast implants and tissue expanders.

Then, on February 14, 2017, Hologic, Inc. (NASDAQ: HOLX) purchased Cynosure, Inc. (NASDAQ: CYNO) for $1.57 billion (or $66.0 per share). Cynosure develops, manufactures and markets aesthetic treatment systems for plastic surgeons, dermatologists and other medical practitioners. It has a portfolio of more than 20 products, including non-invasive body contouring and women’s health. The deal will extend Hologic’s scientific and commercial capabilities into medical aesthetics.